Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

CD47-SIRPα interaction acts as a “don’t eat me” signal and is exploited by cancer to downregulate innate and adaptive immune surveillance. There has been intense interest to develop a mechanism of blockade, and we aimed to analyze the emerging data from early clinical trials. We performed a systemat...

Full description

Bibliographic Details
Main Authors:	Ji Son, Rodney Cheng-En Hsieh, Heather Y. Lin, Kate J. Krause, Ying Yuan, Amadeo B. Biter, James Welsh, Michael A. Curran, David S. Hong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Immunology
Subjects:	CD47 inhibitor SIRPα inhibitor next generation checkpoint inhibition checkpoint inhibitor resistance clinical trial novel therapeutics
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027235/full

Similar Items

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01)

Targeting CD47 as a Novel Immunotherapy for Breast Cancer
by: Can Chen, et al.
Published: (2022-07-01)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
by: Jinyang Hu, et al.
Published: (2020-11-01)

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
by: Leonie M. Behrens, et al.
Published: (2022-07-01)

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
by: Erik Voets, et al.
Published: (2019-12-01)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
by: Jason C. Andrechak, et al.
Published: (2022-04-01)

A New Serum Macrophage Checkpoint Biomarker for Innate Immunotherapy: Soluble Signal-Regulatory Protein Alpha (sSIRPα)
by: Yoanna V. Vladimirova, et al.
Published: (2022-07-01)

SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the “don’t eat me” signal and activating the “eat me” signal
by: Jifeng Yu, et al.
Published: (2022-11-01)

Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
by: Bo Huang, et al.
Published: (2021-01-01)

Crystal Structure of Human CD47 in Complex with Engineered SIRPα.D1(N80A)
by: Jifeng Yu, et al.
Published: (2022-08-01)

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
by: Tracy C. Kuo, et al.
Published: (2020-11-01)

Cancer Therapy Targeting CD47/SIRPα
by: Nazli Dizman, et al.
Published: (2021-12-01)

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
by: Xiuman Zhou, et al.
Published: (2021-05-01)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01)

Regulation of CD47 expression on CD14+ monocytes by interferon-α in PBC patients
by: Xi Su, et al.
Published: (2023-12-01)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
by: Amy Xiao, et al.
Published: (2022-11-01)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
by: Haiqin Liao, et al.
Published: (2022-04-01)

CD47–SIRPα-targeted therapeutics: status and prospects
by: R. Maute, et al.
Published: (2022-03-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
by: Pengcheng Zhao, et al.
Published: (2024-01-01)

CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems
by: Junqiao Zhu, et al.
Published: (2022-09-01)

Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis
by: Xiao-Jing Chen, et al.
Published: (2024-01-01)

Membrane-Mediated Cooperative Interactions of CD47 and SIRP<i>α</i>
by: Long Li, et al.
Published: (2023-11-01)

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9
by: Chilam Chan, et al.
Published: (2023-06-01)

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed
by: Tailong Qu, et al.
Published: (2022-04-01)

Molecular mechanics and dynamics simulation of CD-47/SIRPα blockade study: A computational study on overcoming immunotherapeutic resistance in pancreatic ductal adenocarcinoma
by: Oluwatosin A. Saibu, et al.
Published: (2023-11-01)

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
by: Zhenbin Qiu, et al.
Published: (2019-08-01)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
by: Hui Yang, et al.
Published: (2022-03-01)

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells
by: Sukhbir Kaur, et al.
Published: (2024-03-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
by: Pottayil G. Sasikumar, et al.
Published: (2020-12-01)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
by: Asa P. Y. Lau, et al.
Published: (2023-10-01)

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab
by: Rongmao Gao, et al.
Published: (2023-06-01)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
by: Alexandra S. Zimmer, et al.
Published: (2019-07-01)

Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer
by: Yu Pan, et al.
Published: (2019-11-01)

The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
by: Yu Chang, et al.
Published: (2022-12-01)

Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
by: Alexandra Giatromanolaki, et al.
Published: (2022-04-01)

CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
by: Jennifer Sun, et al.
Published: (2021-01-01)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
by: Jean-Michel Lavoie, et al.
Published: (2021-11-01)